Lower levels of vWF are associated with lower risk of cardiovascular disease
Standard
Lower levels of vWF are associated with lower risk of cardiovascular disease. / van Paridon, Pauline C S; Panova-Noeva, Marina; van Oerle, Rene; Schulz, Andreas; Prochaska, Jürgen H; Arnold, Natalie; Schmidtmann, Irene; Beutel, Manfred; Pfeiffer, Norbert; Münzel, Thomas; Lackner, Karl J; Ten Cate, Hugo; Wild, Philipp S; Spronk, Henri M H.
in: RES PRACT THROMB HAE, Jahrgang 6, Nr. 7, e12797, 10.2022.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Lower levels of vWF are associated with lower risk of cardiovascular disease
AU - van Paridon, Pauline C S
AU - Panova-Noeva, Marina
AU - van Oerle, Rene
AU - Schulz, Andreas
AU - Prochaska, Jürgen H
AU - Arnold, Natalie
AU - Schmidtmann, Irene
AU - Beutel, Manfred
AU - Pfeiffer, Norbert
AU - Münzel, Thomas
AU - Lackner, Karl J
AU - Ten Cate, Hugo
AU - Wild, Philipp S
AU - Spronk, Henri M H
N1 - © 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
PY - 2022/10
Y1 - 2022/10
N2 - OBJECTIVE: The current study was undertaken to prospectively explore whether having low levels of von Willebrand factor (vWF) antigen and vWF activity reduce the risk for cardiovascular disease and death.METHODS: VWF antigen and vWF activity were measured by enzyme-linked immunosorbent assay and an immunological-based assay, respectively, in a subsample of 4857 individuals aged between 35 and 74 years old, enrolled between April 2007 and October 2008 in the population-based Gutenberg Health Study. VWF antigen and activity below the 20th percentile was set as a measure of "low vWF." Adjusted robust Poisson regression models were used to analyze the relation between low vWF and the incidence of cardiovascular disease (CVD). Consequent adjusted cox regression models as well as cumulative incidence plots were calculated to explore the relation between all-cause and cardiovascular mortality and low vWF.RESULTS: VWF activity levels <20th percentile (i.e., <76.2%) were associated with a decreased relative risk for CVD (RR: 0.59, 95% CI: 0.37-0.95), despite adjusting for age and sex. After adjusting for levels of F-VIII, the association persisted (RR: 0.60, 95% CI: 0.36-0.99). The cumulative incidence plots demonstrated that vWF antigen <20th percentile significantly correlated with decreased cardiovascular mortality. VWF antigen<20th percentile (i.e., <83%) was significantly associated with lower risk of all-cause mortality, despite adjusting for clinical factors (RR: 61, 95% CI: 0.41-0.91).CONCLUSION: The study demonstrated that having low vWF activity levels were associated with a lower risk for CVD. Additionally, it revealed a decreased risk of cardiovascular and all-cause mortality in individuals with low levels of vWF antigen, shining new light on vWF as a potential target for novel therapies.
AB - OBJECTIVE: The current study was undertaken to prospectively explore whether having low levels of von Willebrand factor (vWF) antigen and vWF activity reduce the risk for cardiovascular disease and death.METHODS: VWF antigen and vWF activity were measured by enzyme-linked immunosorbent assay and an immunological-based assay, respectively, in a subsample of 4857 individuals aged between 35 and 74 years old, enrolled between April 2007 and October 2008 in the population-based Gutenberg Health Study. VWF antigen and activity below the 20th percentile was set as a measure of "low vWF." Adjusted robust Poisson regression models were used to analyze the relation between low vWF and the incidence of cardiovascular disease (CVD). Consequent adjusted cox regression models as well as cumulative incidence plots were calculated to explore the relation between all-cause and cardiovascular mortality and low vWF.RESULTS: VWF activity levels <20th percentile (i.e., <76.2%) were associated with a decreased relative risk for CVD (RR: 0.59, 95% CI: 0.37-0.95), despite adjusting for age and sex. After adjusting for levels of F-VIII, the association persisted (RR: 0.60, 95% CI: 0.36-0.99). The cumulative incidence plots demonstrated that vWF antigen <20th percentile significantly correlated with decreased cardiovascular mortality. VWF antigen<20th percentile (i.e., <83%) was significantly associated with lower risk of all-cause mortality, despite adjusting for clinical factors (RR: 61, 95% CI: 0.41-0.91).CONCLUSION: The study demonstrated that having low vWF activity levels were associated with a lower risk for CVD. Additionally, it revealed a decreased risk of cardiovascular and all-cause mortality in individuals with low levels of vWF antigen, shining new light on vWF as a potential target for novel therapies.
U2 - 10.1002/rth2.12797
DO - 10.1002/rth2.12797
M3 - SCORING: Journal article
C2 - 36381288
VL - 6
JO - RES PRACT THROMB HAE
JF - RES PRACT THROMB HAE
SN - 2475-0379
IS - 7
M1 - e12797
ER -
